Virtual Library
Start Your Search
HONGXIA Ma
Author of
-
+
P02 - Diagnostics and Interventional Pulmonology (ID 110)
- Event: WCLC 2020
- Type: Posters
- Track: Diagnostics and Interventional Pulmonology
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P02.22 - Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing (ID 2226)
00:00 - 00:00 | Presenting Author(s): HONGXIA Ma
- Abstract
Introduction
Genomic alterations have been described in the fibroblast growth factor receptors (FGFR) in multiple cancer types. Food and Drug Administration (FDA) has approved Balversa (erdafitinib) for metastatic bladder cancer treatment, and more FGFR inhibitors are currently being evaluated clinically in many other cancer types, including lung cancer. Although a lot of works described the translocation or amplifications on FGFR genes in multiple cancers, little is known about the FGFR1-4 genomic alterations in Chinese lung cancers. In the present study, we focused on the FGFR1-4 mutations who might benefit from FGFR inhibitors as well.
Methods
Mutation profiling was performed on 12,580 lung cancer patients from January 2017 to November 2019 by next-generation sequencing (NGS). The mutation patterns of FGFR1-4, as well as its co-occurrence with targeted drug available mutations (EGFR, BRAF, ALK, ROS1 and NTRK1-3) were analyzed.
Results
FGFR mutations were identified in 3.21% of lung cancer patients (404/12580), 105 patients in FGFR1 mutation, 95 in FGFR2, 196 in FGFR3 and 30 in FGFR4. A total of 426 mutations were detected, with the majority being SNVs (89.9%), followed by base deletion (8.5%) and base insertion (1.6%). Co-occurring EGFR actionable alterations were observed in 33.42% of these 404 cases, while concurrent BRAF_V600E was observed in 4 additional cases, and coexistence with ROS1 or ALK fusions were observed in 2.72% cases. Druggable FGFR mutations with biological evidence or FDA approval were detected in 5.45% (22/404) of patients, including FGFR2_S252W (1/22), FGFR2_Y375C (1/22), FGFR3_R248C (6/22) and FGFR3_S249C (14/22). There was only one FDA-approved actionable variation (BRAF_V600E) found in these 22 druggable FGFR positive cases, suggesting a mutually exclusive relationship between FGFR actionable mutations and other actionable variations.
Conclusion
FGFR aberrations are common in a wide variety of cancers. FGFR is a potential druggable gene and FDA has approved Balversa (erdafitinib) for treating metastatic bladder cancer patients with FGFR2 fusions, FGFR3 fusions, FGFR3_R248C, FGFR3_S249C, FGFR3_G370C or FGFR3_Y373C. Hopefully, more patients with other FGFR mutations may benefit from FGFR inhibitors as well, which needs further clinical investigation. Meanwhile, the exclusive relationship between druggable FGFR mutations and other actionable variations in lung cancers defines a unique molecular subtype, extending the number of patients who can benefit from targeted therapy.
